Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis

Annals of Neurology

Volumn 43, Issue 3, 1998, Pages 332-339

  Molyneux, P D ^a   Filippi, M ^b   Barkhof, F ^c   Gasperini, C ^d   Yousry, T A ^e   Truyen, L ^c   Lai, H M ^a   Rocca, M A ^b   Moseley, I F ^a   Miller, D H ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM;

ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN SCINTISCANNING; BRAIN SIZE; CLINICAL ARTICLE; DIAGNOSTIC VALUE; DISABILITY; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HUMAN; IMAGE ENHANCEMENT; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS;

EID: 0031891592     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410430311     Document Type: Article

References (38)

1. Miller DH, Albert PS, Barkhof F, et al. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. Ann Neurol 1996;39:6-16
2. Zhao GJ, Li DKB, Wolinsky JS, et al. Clinical and magnetic resonance imaging changes correlate in a clinical trial monitoring cyclosporine therapy for multiple sclerosis. J Neuroimaging 1997;7:1-7
3. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294
4. Paty DW, Li DKB, UBC MS/MRI Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. MRI analysis results of a multicenter, randomised, double-blind, placebo-controlled trial. Neurology 1993;43:662-667
5. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-β on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in multiple sclerosis. Ann Neurol 1995;37:611-619
6. Edan G, Miller D, Clanet, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997; 62:112-118
7. Barkhof F, Filippi M, Miller DH, et al. Strategies for optimising MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244:76-84
8. Barkhof F. MRI in the assessment of putative treatments for multiple sclerosis. Imaging 1996;8:103-115
9. Nesbit GM, Forbes GS, Scheithauer BW, et al. Multiple sclerosis: histopathologic and MR and/or CT correlation in 37 cases at biopsy and three cases at autopsy. Radiology 1991;180: 467-474
10. Rodriguez M, Scheithauer BW, Forbes G, et al. Oligodendrocyte injury is an early event in lesions of multiple sclerosis. Mayo Clin Proc 1993;68:627-636
11. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452
14. van Walderveen MA, Barkhof F, Hommes OR, et al. Correlating MRI and clinical disease activity in multiple sclerosis: relevance of hypointense lesions on short-TR/short-TE (T1-weighted) spin echo images. Neurology 1995;45:1684-1690
15. Plummer DL. Dispimage: a display and analysis tool for medical images. Riv Neuroradiol 1992;5:489-495
16. Grimaud J, Lai M, Thorpe J, et al. Quantification of MRI lesion load in MS: a comparison of three computer-assisted techniques. Magn Reson Imaging 1996;14:495-505
17. Thompson AJ, Miller DH, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42:60-63
18. Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 1993;33:480-489
19. Capra R, Marciano N, Vignolo LA, et al. Gadolinium-pentitic acid magnetic resonance imaging in patients with relapsing-remitting multiple sclerosis. Arch Neurol 1992;49:687-689
20. Frank JA, Stone LA, Smith M, et al. Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 1994;36:S86-90
21. Khoury SJ, Guttman CRG, Orav EJ, et al. Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology 1994;44:2120-2124
22. Miller DH, Barkhof F, Nauta JJP. Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 1993;16:1077-1094
23. Kermode AG, Tofts PS, Thompson AJ, et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DPTA enhancement. Neurology 1990;40: 229-235
24. Harris JO, Frank JA, Patronas N, et al. Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 1991;29:548-555
25. Silver NC, Good CD, Barker GJ, et al. Sensitivity of contrast enhanced MRI in multiple sclerosis: effects of gadolinium dose, magnetisation transfer contrast and delayed imaging. Brain 1997;120:1149-1161
26. Filippi M, Yousry T, Campi A, et al. Comparison of triple dose versus standard dose gadolinium-DPTA for detection of MRI enhancing lesions in patients with MS. Neurology 1996:46; 379-384
27. Barkhof F, Filippi M, van Waesberghe JH, et al. Interobserver variation in reporting gadolinium-enhanced MS lesions: consensus rules and effect of training. Proc Int Soc Magn Reson Med 1997;1:640
28. Filippi M, Horsfield MA, Tofts PS, et al. Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. Brain 1995;118:1601-1612
29. Fleiss JL, ed. The design and analysis of clinical experiments. New York: John Wiley & Sons, 1985
30. Gawne-Cain ML, Webb S, PS Tofts, et al. Lesion volume measurement in MS: how important is accurate repositioning? J Magn Reson Imaging 1996;6:705-713
31. Willoughby EW, Grochowski E, Li DBK, et al. Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 1989;25:43-49
32. Isaac C, Li DKB, Genton M, et al. Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology 1988;38: 1511-1515
33. Kermode AG, Thompson AJ, Tofts PS, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Brain 1990;113:1477-1489
34. McDonald WI, Miller DH, Barnes D. The pathological evolution of multiple sclerosis. Neuropathol Appl Neurobiol 1992; 18:319-334
35. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
36. Koudriavtesa T, Thompson AJ, Fiorelli M, et al. Gadolinium-enhanced MRI predicts clinical and MRI activity in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1997;62:285-287
37. Filippi M, Paty DW, Kappos L, et al. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology 1995;45:255-260
38. Losseff NA, Kingsley DPE, McDonald WI, et al. Clinical and magnetic resonance predictors of disability in primary and secondary progressive multiple sclerosis. Multiple Sclerosis 1996;1: 218-222